{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:36:20Z","timestamp":1771256180056,"version":"3.50.1"},"reference-count":104,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1517\/17425255.2011.575061","type":"journal-article","created":{"date-parts":[[2011,4,9]],"date-time":"2011-04-09T02:36:08Z","timestamp":1302316568000},"page":"829-846","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacokinetics and metabolism update for some recent antipsychotics"],"prefix":"10.1517","volume":"7","author":[{"given":"Silvio","family":"Caccia","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,4,8]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurx.2005.12.003"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000298097"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502001-00002"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105058378"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.1.9"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"issue":"8","key":"e_1_3_2_12_1","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians","volume":"23","author":"Naber D","year":"2009","unstructured":"Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009;23(8):649-59","journal-title":"CNS Drugs"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371005500302"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00010"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301071"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790361461"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.05.025"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.12.006"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.05.016"},{"key":"e_1_3_2_20_1","first-page":"CD004578","article-title":"Aripiprazole for schizophrenia","volume":"2","author":"El-Sayeh HG","year":"2006","unstructured":"El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_21_1","first-page":"CD006617","article-title":"Aripiprazole versus typical antipsychotic drugs for schizophrenia","volume":"3","author":"Bhattacharjee J","year":"2008","unstructured":"Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008;3:CD006617","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.54.478"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.93.114"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.10.015"},{"issue":"1","key":"e_1_3_2_25_1","first-page":"121","article-title":"Perospirone (Sumitomo Pharmaceuticals)","volume":"3","author":"de Paulis T","year":"2002","unstructured":"de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs 2002;3(1):121-9","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115040-00006"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01947.x"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04905"},{"issue":"6","key":"e_1_3_2_30_1","first-page":"227","article-title":"Efficacy of lurasidone: summary of results from the clinical development program","volume":"70","author":"Loebel A","year":"2010","unstructured":"Loebel A, Cucchiaro J, Ogasa M, Efficacy of lurasidone: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010;70(6):227-8","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_2_31_1","first-page":"2","article-title":"A three arm dose finding study of lurasidone; efficacy and tolerability data","volume":"117","author":"Harwey PD","year":"2010","unstructured":"Harwey PD, Murasaki M, Cucchiaro J, A three arm dose finding study of lurasidone; efficacy and tolerability data. Schizophr Res 2010;117:2-3 (374-375)","journal-title":"Schizophr Res"},{"key":"e_1_3_2_32_1","first-page":"217","article-title":"Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia","volume":"13","author":"Cucchiaro J","year":"2010","unstructured":"Cucchiaro J, Pikalow A, Ogasa M, Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol 2010;13(Suppl. S1):abstract P-20.021, 217","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_2_33_1","first-page":"88","article-title":"The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia","author":"Bose A","year":"2010","unstructured":"Bose A, Li D, Migliore R, The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Int J Neuropsychopharmacol 2010;abstract P-04.012, 88","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_2_34_1","first-page":"s1","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"11","author":"Knesevich MA","year":"2009","unstructured":"Knesevich MA, Papadakis K, Bose A, The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2009;11:s1 (54)","journal-title":"Bipolar Disord"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432"},{"issue":"7","key":"e_1_3_2_36_1","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics","volume":"8","author":"Newman-Tancredi A","year":"2007","unstructured":"Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54","journal-title":"Curr Opin Investig Drugs"},{"issue":"7","key":"e_1_3_2_37_1","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi A","year":"2010","unstructured":"Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-12","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.01.021"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388"},{"issue":"7","key":"e_1_3_2_40_1","first-page":"823","article-title":"Cariprazine, an orally active D2\/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression","volume":"11","author":"Grunder G","year":"2010","unstructured":"Grunder G. Cariprazine, an orally active D2\/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11(7):823-32","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_41_1","unstructured":"Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. Sunovion Pharmaceuticals Inc. Clinical Review; Pharmacology Review(s); Clinical Pharmacology Biopharmaceutics Review(s). Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search. Drug-Details [Last accessed November 2010]"},{"issue":"11","key":"e_1_3_2_42_1","first-page":"12","article-title":"Pharmacokinetics and drug interactions: update for new antipsychotics","volume":"57","author":"Ereshefsky L","year":"1996","unstructured":"Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(Suppl 11):12-25","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920010791636202"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038050-00002"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200002000-00025"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.58.7.0001"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784746373"},{"key":"e_1_3_2_48_1","unstructured":"Latuda (lurasidone HCl) (Prescribing Information). Sunovion Pharmaceutical Inc. Available from: http:\/\/latuda.com\/latudaprescribinginformation.pdf. [Last accessed November 2010]"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847070-00004"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00067-9"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200408000-00004"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261901"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00304-4"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06091479"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2007.05.002"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000236659.93415.4a"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1783-1"},{"key":"e_1_3_2_58_1","unstructured":"Abilify (Aripiprazole) Tablets: Otsuka Pharmaceutical Co. Ltd. Drug Approval Package.Application no.: 21-436 Clinical Pharmacology Biopharmaceutics Review(S). Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-436_abilify.cfm. [Last accessed 4 November 2010]"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920007781368908"},{"key":"e_1_3_2_60_1","article-title":"In vitro metabolismo of RGH-188","volume":"40","author":"Kirschner N","year":"2008","unstructured":"Kirschner N, Gemesi LI, Vastag M, In vitro metabolismo of RGH-188. Drug Metab Rev 2008;40:abstract 182","journal-title":"Drug Metab Rev"},{"issue":"4","key":"e_1_3_2_61_1","article-title":"Pharmacokinetics of RGH-188, a new dopamine D3\/D2 antagonist\/partial agonist atypical antipsychotic candidate","volume":"217","author":"Meszaros GP","year":"2007","unstructured":"Meszaros GP, Kapas M, Borsos M, Pharmacokinetics of RGH-188, a new dopamine D3\/D2 antagonist\/partial agonist atypical antipsychotic candidate. Eur Neuropsychopharmacol 2007;217(Suppl 4):abstract p.3.c.0.47","journal-title":"Eur Neuropsychopharmacol"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.12.016"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.02.012"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.10.008"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.03.027"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190868"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.432"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.10.974"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07101574"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701361255"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000249944.42859.bf"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.06.010"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.07.008"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.55"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.2.171"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903081738"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09r05060gre"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050047"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000185767.59749.bb"},{"key":"e_1_3_2_80_1","unstructured":"Aripiprazole\/Abilify (Prescribing Information). Bristol-Myers Squibb Otsuka Pharmaceutical America Inc. Rev November 2009. Available from: http:\/\/www.abilify.com. [Last accessed October 2010]"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03223.x"},{"key":"e_1_3_2_82_1","unstructured":"Chiu Y Nielsen J Sarrubi D Kowalski K. Population pharmacokinetics of lurasidone in healthy subjects and subjects with schizophrenia [abstract 1729]. Annual meeting of the population approach group in Europe; 2010. p. 19. Available from: www.page-meeting.org\/?"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629070-00004"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531730-000000000-00000"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623120-00002"},{"issue":"3","key":"e_1_3_2_86_1","first-page":"250","article-title":"Focus on aripiprazole: a review of its use in child and adolescent psychiatry","volume":"18","author":"Greenaway M","year":"2009","unstructured":"Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18(3):250-60","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.2217\/phe.10.45"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817dd520"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318178e18d"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.1.3.447"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819f3328"},{"key":"e_1_3_2_92_1","doi-asserted-by":"crossref","unstructured":"Caccia S Clavenna A Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 15 March 2011 [Epub ahead of print]","DOI":"10.1517\/17425255.2011.562198"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847080-00003"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.22.358"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0373-6"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-977715"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181956726"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190869"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.01.011"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)01680-6"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0487-5"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0055-0"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746050-00001"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S6591"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S6443"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.49.4.347"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425255.2011.575061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:27:09Z","timestamp":1770917229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425255.2011.575061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,8]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1517\/17425255.2011.575061"],"URL":"https:\/\/doi.org\/10.1517\/17425255.2011.575061","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,8]]}}}